HopeStage
Back to all studies
RecruitingNCT05052853

NMDA enhancer or placebo for early signs of schizophrenia

About this titleRead the official source — NCT05052853
Medication studyAges 13–45Taiwan
The study in practice

Understand this study

Who could participate?

Listed age limits: 13 years to 45 years.

Listed locations
TaichungSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 1, 2021
Recruitment status
Recruiting
Enrollment listed in the registry
48
Sponsor
China Medical University Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Taiwan
Age range
From 13 Years to 45 Years
Official registry ID
NCT05052853
Official title
Show the full official title

Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer

Recruitment & locations

Currently recruiting

Taichung

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is China Medical University Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including NMDAE and Placebo Cap.

Who can participate?

Listed age limits: 13 years to 45 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies